2 news items
GlycoMimetics Announces Results of Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)
GLYC
6 May 24
, clinical trials; potential development and regulatory activities; and the potential benefits and impact of uproleselan. Actual results may differ
GlycoMimetics Reports Highlights and Financial Results for Fourth Quarter and Full Year 2023
GLYC
27 Mar 24
or potential clinical development, regulatory interactions, or submissions; the company's collaborations with third parties; and the potential benefits
- Prev
- 1
- Next